Pharmacology of antiplatelet agents

Kiran Kalra, Christopher J. Franzese, Martin G. Gesheff, Eli I. Lev, Shachi Pandya, Kevin P. Bliden, Udaya S. Tantry, Paul A. Gurbel

Research output: Contribution to journalArticlepeer-review

Abstract

Pharmacotherapies with agents that inhibit platelet function have proven to be effective in the treatment of acute coronary syndromes, and in the prevention of complications during and after percutaneous coronary intervention. Because of multiple synergetic pathways of platelet activation and their close interplay with coagulation, current treatment strategies are based not only on platelet inhibition, but also on the attenuation of procoagulant activity, inhibition of thrombin generation, and enhancement of clot dissolution. Current strategies can be broadly categorized as anticoagulants, antiplatelet agents, and fibrinolytics. This review focuses on the pharmacology of current antiplatelet therapy primarily targeting the inhibition of the enzyme cyclooxygenase 1, the P2Y12 receptor, the glycoprotein IIb/IIIa receptor, and protease-activated receptor 1.

Original languageEnglish (US)
Article number371
JournalCurrent atherosclerosis reports
Volume15
Issue number12
DOIs
StatePublished - Dec 2013

Keywords

  • Acute coronary syndromes
  • Aspirin
  • Clopidogrel
  • Glycoprotein IIb/IIIa inhibitors
  • P2Y receptor blockers
  • Platelets
  • Prasugrel
  • Protease-activated receptor 1 inhibitors
  • Ticagrelor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Pharmacology of antiplatelet agents'. Together they form a unique fingerprint.

Cite this